[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100374056":3},{"organization":4,"outcomesModule":7,"designInfo":33,"detailedDescription":15,"studyPopulation":15,"armGroups":39,"interventions":47,"overallOfficials":59,"centralContacts":64,"locations":70,"responsibleParty":251,"collaborators":15,"id":253,"slug":15,"hasResults":254,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":15,"eligibilityCriteria":258,"healthyVolunteers":254,"sex":259,"minAge":260,"maxAge":261,"enrollmentInfo":262,"targetDuration":15,"studyType":265,"phases":266,"briefSummary":269,"conditions":270,"keywords":272,"overallStatus":73,"whyStopped":15,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":287},{"fullName":5,"class":6},"Cellectis S.A.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":15},[9,13],{"measure":10,"description":11,"timeFrame":12},"Incidence of AE\u002FSAE\u002FDLT [Safety and Tolerability]","Incidence, nature, and severity of adverse events and serious adverse events (SAEs) throughout the study in relation to UCART22 and\u002For lymphodepletion","24 Months",{"measure":14,"description":15,"timeFrame":16},"Dose escalation part: Occurrence of Dose Limiting Toxicities (DLTs)",null,"Up to D28 post initial UCART22 infusion",[18,21,24,27,30],{"measure":19,"description":15,"timeFrame":20},"Investigator assessed overall response rate according to the Response criteria for Acute Lymphoblastic Leukemia (ALL)","At Day 28, Day 56, Day 84, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21 and Month 24",{"measure":22,"description":15,"timeFrame":23},"Duration of Response","From the date of the initial response to the date of disease progression or death from any cause, whichever occurs first, assessed up to Month 24",{"measure":25,"description":15,"timeFrame":26},"Progression Free Survival","From the first day of study treatment to the date of disease progression or death from any cause, whichever occurs first, assessed up to Month 24",{"measure":28,"description":15,"timeFrame":29},"Overall Survival","From the first day of study treatment to the date of death from any cause, assessed up to Month 24",{"measure":31,"description":15,"timeFrame":32},"Pharmacokinetic (PK) profile\u002Fexposure levels of CLLS52 (Alemtuzumab) used during lymphodepletion","Lymphodepletion to Day 56",{"allocation":34,"interventionModel":35,"interventionModelDescription":15,"primaryPurpose":36,"observationalModel":15,"timePerspective":15,"maskingInfo":37},"NA","SINGLE_GROUP","TREATMENT",{"masking":38,"maskingDescription":15,"whoMasked":15},"NONE",[40],{"label":41,"type":42,"description":43,"interventionNames":44},"Dose Escalation","EXPERIMENTAL","Several tested doses of UCART22 until the Maximum Tolerated Dose (MTD) is identified and establish Recommended Phase 2 Dose (RP2D)\n\nDose Expansion: UCART22 administered at the RP2D",[45,46],"Biological: UCART22","Biological: CLLS52",[48,53],{"type":49,"name":50,"description":51,"armGroupLabels":52,"otherNames":15},"BIOLOGICAL","UCART22","Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen",[41],{"type":49,"name":54,"description":55,"armGroupLabels":56,"otherNames":57},"CLLS52","A monoclonal antibody that recognizes a CD52 antigen",[41],[58],"Alemtuzumab",[60],{"name":61,"affiliation":62,"role":63},"Nitin Jain, MD","M.D. Anderson Cancer Center","PRINCIPAL_INVESTIGATOR",[65],{"name":66,"role":67,"phone":68,"phoneExt":15,"email":69},"Cellectis Central Contact","CONTACT","+1 (347) 752-4044","clinicaltrials@cellectis.com",[71,85,95,104,114,124,134,142,149,159,169,179,188,197,207,218,227,233,242],{"facility":72,"status":73,"city":74,"state":75,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":79,"geoPoint":84,"contacts":15},"University of California, Los Angeles (UCLA) - Medical Center","RECRUITING","Los Angeles","California","90095","United States","US",{"type":80,"coordinates":81},"Point",[82,83],-118.24368,34.05223,{"lat":83,"lon":82},{"facility":86,"status":73,"city":87,"state":88,"zip":89,"country":77,"countryCode":78,"cosmosGeoPoint":90,"geoPoint":94,"contacts":15},"University of Colorado - Aurora Cancer Center","Aurora","Colorado","80045",{"type":80,"coordinates":91},[92,93],-104.83192,39.72943,{"lat":93,"lon":92},{"facility":96,"status":73,"city":97,"state":88,"zip":98,"country":77,"countryCode":78,"cosmosGeoPoint":99,"geoPoint":103,"contacts":15},"Sarah Cannon - Colorado Blood Cancer Institute","Denver","80218",{"type":80,"coordinates":100},[101,102],-104.9847,39.73915,{"lat":102,"lon":101},{"facility":105,"status":73,"city":106,"state":107,"zip":108,"country":77,"countryCode":78,"cosmosGeoPoint":109,"geoPoint":113,"contacts":15},"University of Chicago","Chicago","Illinois","60647",{"type":80,"coordinates":110},[111,112],-87.65005,41.85003,{"lat":112,"lon":111},{"facility":115,"status":73,"city":116,"state":117,"zip":118,"country":77,"countryCode":78,"cosmosGeoPoint":119,"geoPoint":123,"contacts":15},"Dana Farber Cancer Institute","Boston","Massachusetts","02215",{"type":80,"coordinates":120},[121,122],-71.05977,42.35843,{"lat":122,"lon":121},{"facility":125,"status":73,"city":126,"state":127,"zip":128,"country":77,"countryCode":78,"cosmosGeoPoint":129,"geoPoint":133,"contacts":15},"Roswell Park Comprehensive Cancer Center","Buffalo","New York","14263",{"type":80,"coordinates":130},[131,132],-78.87837,42.88645,{"lat":132,"lon":131},{"facility":135,"status":73,"city":127,"state":127,"zip":136,"country":77,"countryCode":78,"cosmosGeoPoint":137,"geoPoint":141,"contacts":15},"Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center","10021",{"type":80,"coordinates":138},[139,140],-74.00597,40.71427,{"lat":140,"lon":139},{"facility":143,"status":144,"city":127,"state":127,"zip":145,"country":77,"countryCode":78,"cosmosGeoPoint":146,"geoPoint":148,"contacts":15},"Weill Medical College of Cornell University","WITHDRAWN","10065",{"type":80,"coordinates":147},[139,140],{"lat":140,"lon":139},{"facility":150,"status":73,"city":151,"state":152,"zip":153,"country":77,"countryCode":78,"cosmosGeoPoint":154,"geoPoint":158,"contacts":15},"Children's Hospital of Philadelphia","Philadelphia","Pennsylvania","19104",{"type":80,"coordinates":155},[156,157],-75.16362,39.95238,{"lat":157,"lon":156},{"facility":160,"status":73,"city":161,"state":162,"zip":163,"country":77,"countryCode":78,"cosmosGeoPoint":164,"geoPoint":168,"contacts":15},"Sarah Cannon - HCA Research Institute","Nashville","Tennessee","37203",{"type":80,"coordinates":165},[166,167],-86.78444,36.16589,{"lat":167,"lon":166},{"facility":170,"status":73,"city":171,"state":172,"zip":173,"country":77,"countryCode":78,"cosmosGeoPoint":174,"geoPoint":178,"contacts":15},"Sarah Cannon - St. David's South Austin Medical Center","Austin","Texas","78704",{"type":80,"coordinates":175},[176,177],-97.74306,30.26715,{"lat":177,"lon":176},{"facility":180,"status":73,"city":181,"state":172,"zip":182,"country":77,"countryCode":78,"cosmosGeoPoint":183,"geoPoint":187,"contacts":15},"MD Anderson Cancer Center","Houston","77030",{"type":80,"coordinates":184},[185,186],-95.36327,29.76328,{"lat":186,"lon":185},{"facility":189,"status":73,"city":190,"state":172,"zip":191,"country":77,"countryCode":78,"cosmosGeoPoint":192,"geoPoint":196,"contacts":15},"Sarah Cannon - Texas Transplant Institute at Methodist Hospital","San Antonio","78229",{"type":80,"coordinates":193},[194,195],-98.49363,29.42412,{"lat":195,"lon":194},{"facility":198,"status":73,"city":199,"state":200,"zip":201,"country":77,"countryCode":78,"cosmosGeoPoint":202,"geoPoint":206,"contacts":15},"University of Wisconsin Carbone Cancer Center","Madison","Wisconsin","53792",{"type":80,"coordinates":203},[204,205],-89.40123,43.07305,{"lat":205,"lon":204},{"facility":208,"status":73,"city":209,"state":15,"zip":210,"country":211,"countryCode":212,"cosmosGeoPoint":213,"geoPoint":217,"contacts":15},"CHU de Nantes - Hôtel-Dieu","Nantes","44093","France","FR",{"type":80,"coordinates":214},[215,216],-1.55336,47.21725,{"lat":216,"lon":215},{"facility":219,"status":73,"city":220,"state":15,"zip":221,"country":211,"countryCode":212,"cosmosGeoPoint":222,"geoPoint":226,"contacts":15},"Hôpital Saint Louis, Unité d'Hématologie Adolescents et Jeunes Adultes Département d'Hématologie","Paris","75010",{"type":80,"coordinates":223},[224,225],2.3488,48.85341,{"lat":225,"lon":224},{"facility":228,"status":73,"city":220,"state":15,"zip":229,"country":211,"countryCode":212,"cosmosGeoPoint":230,"geoPoint":232,"contacts":15},"Hôpital Robert Debré - Service d'hémato-immunologie","75019",{"type":80,"coordinates":231},[224,225],{"lat":225,"lon":224},{"facility":234,"status":73,"city":235,"state":15,"zip":236,"country":211,"countryCode":212,"cosmosGeoPoint":237,"geoPoint":241,"contacts":15},"Hôpital Lyon Sud","Pierre-Bénite","69310",{"type":80,"coordinates":238},[239,240],4.82424,45.70359,{"lat":240,"lon":239},{"facility":243,"status":73,"city":244,"state":15,"zip":245,"country":211,"countryCode":212,"cosmosGeoPoint":246,"geoPoint":250,"contacts":15},"CHU Rennes - Hopital Pontchaillou","Rennes","35033",{"type":80,"coordinates":247},[248,249],-1.67431,48.11109,{"lat":249,"lon":248},{"type":252,"investigatorFullName":15,"investigatorTitle":15,"investigatorAffiliation":15,"oldNameTitle":15,"oldOrganization":15},"SPONSOR","100374056",false,"NCT04150497","Phase 1\u002F2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)","Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in Patients With Relapsed or refractoryCD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)","Inclusion Criteria:\n\n* B-ALL blast cells expressing CD22\n* Diagnosed with R\u002FR B-ALL\n* Prior therapy must include at least one standard chemotherapy regimen and at least one salvage regimen\n\nExclusion Criteria:\n\n-Prior cellular therapy or investigational cellular or gene therapy within 90 days prior to enrollment","ALL","15 Years","50 Years",{"count":263,"type":264},52,"ESTIMATED","INTERVENTIONAL",[267,268],"PHASE1","PHASE2","This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety and clinical activity of UCART22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)",[271],"B-cell Acute Lymphoblastic Leukemia",[273,274,275,276,277],"B-cell Acute Lymphoblastic Leukemia (B-ALL)","Relapse\u002FRefractory B-ALL","Universal Chimeric Antigen Receptor T-Cell (UCAR-T) Therapy","Allogeneic","Transcription Activator-Like Effector Nuclease (TALEN®)","2025-09-08",{"date":280,"type":281},"2025-09-09","ACTUAL",{"date":283,"type":281},"2019-10-14",{"date":285,"type":264},"2026-06-30",{"name":5,"class":6},19]